Unlock the therapeutic potential of Vasoactive Intestinal Peptide (VIP), a powerful 28-amino acid neuropeptide with promising applications for respiratory health, erectile dysfunction, and inflammatory disorders. While it's still on the path to FDA approval, VIP's vasodilatory and immunomodulatory properties could revolutionize treatment options as early as December 2025.
Mechanism
VIP engages VPAC1 and VPAC2, G protein-coupled receptors that elevate intracellular cAMP levels. This initiates a cascade that relaxes smooth muscle, dilates blood vessels, and fine-tunes immune responses, making it a candidate for alleviating conditions like pulmonary hypertension and acute respiratory distress. By driving bronchodilation and modulating T-cell functions, VIP stands out in treating inflammatory conditions.
Research
Clinical research highlights VIP's potential, including its FDA Fast Track Designation for addressing COVID-19-related respiratory failure and promising outcomes in erectile dysfunction when combined with phentolamine (Invicorp). Trials have shown VIP's beneficial impacts on patient oxygenation and survival during ARDS, yet it remains awaiting FDA approval for these uses.
Synergies
VIP offers exciting possibilities when paired with therapies targeting inflammation and vascular health, amplifying benefits in respiratory and autoimmune conditions. Ben IQ harnesses YOUR lab results and objectives to optimize therapeutic combinations.
Trade-Offs
Considerations for VIP include its ultra-short half-life, which may necessitate continuous infusion methods, and the potential for immunosuppression impacting infection resilience. Tailored considerations demand personalized data on YOUR situation.